Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis

Ankit Bharat, Kishore Narayanan, Anjali Golocheikine, Nancy Steward, Jeffrey Crippin, Mauricio Lisker-Melman, Surendra Shenoy, Jeffrey Lowell, William C. Chapman, Thalachallour Mohanakumar*

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) significantly accelerates progression to allograft cirrhosis. Current biochemical parameters to monitor progression of chronic HCV after OLT have yielded low specificity and sensitivity. Here we investigated the HCV-specific immunity and serum levels of soluble CD30 (sCD30), a novel marker of Th2 immunity, in patients with and without allograft cirrhosis. Patients with hepatic inflammation but no cirrhosis (HIN, n=20) revealed elevated serum interferon (IFN)-γ and high frequency of IFN-γ producing CD4 T(h1) cells compared to those with hepatic cirrhosis (HFC, n=20) that had high interleukin (IL)-5 and IL-5 producing CD4 T(h2) cells. Patients with HFC, but not HIN, were found to have significantly higher levels of sCD30. Therefore, we conclude that lack of optimal Th1-type CD4 T cells is associated with HCV-induced allograft cirrhosis. Further, sCD30 may represent a novel marker for surveillance of hepatic cirrhosis in transplant recipients with chronic HCV infection.

Original languageEnglish (US)
Pages (from-to)1704-1707
Number of pages4
JournalTransplantation
Volume84
Issue number12
DOIs
StatePublished - Dec 1 2007

Fingerprint

Hepacivirus
Liver Cirrhosis
Allografts
Fibrosis
Interleukin-5
Chronic Hepatitis C
Liver Transplantation
Interferons
Immunity
Virus Diseases
Serum
Inflammation
T-Lymphocytes
Recurrence
Sensitivity and Specificity
Liver

Keywords

  • Hepatitis C virus
  • Liver transplantation
  • Soluble CD30

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Bharat, A., Narayanan, K., Golocheikine, A., Steward, N., Crippin, J., Lisker-Melman, M., ... Mohanakumar, T. (2007). Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis. Transplantation, 84(12), 1704-1707. https://doi.org/10.1097/01.tp.0000295973.31877.7b
Bharat, Ankit ; Narayanan, Kishore ; Golocheikine, Anjali ; Steward, Nancy ; Crippin, Jeffrey ; Lisker-Melman, Mauricio ; Shenoy, Surendra ; Lowell, Jeffrey ; Chapman, William C. ; Mohanakumar, Thalachallour. / Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis. In: Transplantation. 2007 ; Vol. 84, No. 12. pp. 1704-1707.
@article{51f4ed4fd8a643d1bd6c8260762b93f0,
title = "Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis",
abstract = "Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) significantly accelerates progression to allograft cirrhosis. Current biochemical parameters to monitor progression of chronic HCV after OLT have yielded low specificity and sensitivity. Here we investigated the HCV-specific immunity and serum levels of soluble CD30 (sCD30), a novel marker of Th2 immunity, in patients with and without allograft cirrhosis. Patients with hepatic inflammation but no cirrhosis (HIN, n=20) revealed elevated serum interferon (IFN)-γ and high frequency of IFN-γ producing CD4 T(h1) cells compared to those with hepatic cirrhosis (HFC, n=20) that had high interleukin (IL)-5 and IL-5 producing CD4 T(h2) cells. Patients with HFC, but not HIN, were found to have significantly higher levels of sCD30. Therefore, we conclude that lack of optimal Th1-type CD4 T cells is associated with HCV-induced allograft cirrhosis. Further, sCD30 may represent a novel marker for surveillance of hepatic cirrhosis in transplant recipients with chronic HCV infection.",
keywords = "Hepatitis C virus, Liver transplantation, Soluble CD30",
author = "Ankit Bharat and Kishore Narayanan and Anjali Golocheikine and Nancy Steward and Jeffrey Crippin and Mauricio Lisker-Melman and Surendra Shenoy and Jeffrey Lowell and Chapman, {William C.} and Thalachallour Mohanakumar",
year = "2007",
month = "12",
day = "1",
doi = "10.1097/01.tp.0000295973.31877.7b",
language = "English (US)",
volume = "84",
pages = "1704--1707",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

Bharat, A, Narayanan, K, Golocheikine, A, Steward, N, Crippin, J, Lisker-Melman, M, Shenoy, S, Lowell, J, Chapman, WC & Mohanakumar, T 2007, 'Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis', Transplantation, vol. 84, no. 12, pp. 1704-1707. https://doi.org/10.1097/01.tp.0000295973.31877.7b

Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis. / Bharat, Ankit; Narayanan, Kishore; Golocheikine, Anjali; Steward, Nancy; Crippin, Jeffrey; Lisker-Melman, Mauricio; Shenoy, Surendra; Lowell, Jeffrey; Chapman, William C.; Mohanakumar, Thalachallour.

In: Transplantation, Vol. 84, No. 12, 01.12.2007, p. 1704-1707.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis

AU - Bharat, Ankit

AU - Narayanan, Kishore

AU - Golocheikine, Anjali

AU - Steward, Nancy

AU - Crippin, Jeffrey

AU - Lisker-Melman, Mauricio

AU - Shenoy, Surendra

AU - Lowell, Jeffrey

AU - Chapman, William C.

AU - Mohanakumar, Thalachallour

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) significantly accelerates progression to allograft cirrhosis. Current biochemical parameters to monitor progression of chronic HCV after OLT have yielded low specificity and sensitivity. Here we investigated the HCV-specific immunity and serum levels of soluble CD30 (sCD30), a novel marker of Th2 immunity, in patients with and without allograft cirrhosis. Patients with hepatic inflammation but no cirrhosis (HIN, n=20) revealed elevated serum interferon (IFN)-γ and high frequency of IFN-γ producing CD4 T(h1) cells compared to those with hepatic cirrhosis (HFC, n=20) that had high interleukin (IL)-5 and IL-5 producing CD4 T(h2) cells. Patients with HFC, but not HIN, were found to have significantly higher levels of sCD30. Therefore, we conclude that lack of optimal Th1-type CD4 T cells is associated with HCV-induced allograft cirrhosis. Further, sCD30 may represent a novel marker for surveillance of hepatic cirrhosis in transplant recipients with chronic HCV infection.

AB - Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) significantly accelerates progression to allograft cirrhosis. Current biochemical parameters to monitor progression of chronic HCV after OLT have yielded low specificity and sensitivity. Here we investigated the HCV-specific immunity and serum levels of soluble CD30 (sCD30), a novel marker of Th2 immunity, in patients with and without allograft cirrhosis. Patients with hepatic inflammation but no cirrhosis (HIN, n=20) revealed elevated serum interferon (IFN)-γ and high frequency of IFN-γ producing CD4 T(h1) cells compared to those with hepatic cirrhosis (HFC, n=20) that had high interleukin (IL)-5 and IL-5 producing CD4 T(h2) cells. Patients with HFC, but not HIN, were found to have significantly higher levels of sCD30. Therefore, we conclude that lack of optimal Th1-type CD4 T cells is associated with HCV-induced allograft cirrhosis. Further, sCD30 may represent a novel marker for surveillance of hepatic cirrhosis in transplant recipients with chronic HCV infection.

KW - Hepatitis C virus

KW - Liver transplantation

KW - Soluble CD30

UR - http://www.scopus.com/inward/record.url?scp=37549039499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549039499&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000295973.31877.7b

DO - 10.1097/01.tp.0000295973.31877.7b

M3 - Article

VL - 84

SP - 1704

EP - 1707

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -